Tech Company Financing Transactions

3-V Biosciences Funding Round

3-V Biosciences, based in Menlo Park, secured $28.5 million from Kleiner Perkins Caufield & Byers, New Enterprise Associates and Rock Springs Capital.

Transaction Overview

Company Name
3-V Biosciences
Announced On
12/31/2014
Transaction Type
Venture Equity
Amount
$28,500,000
Round
Series D
Investors

Kleiner Perkins Caufield & Byers (Lead Investor) (Beth Seidenberg)

New Enterprise Associates (Lead Investor) (Robert Garland)

Rock Springs Capital (Lead Investor)

Ally Bridge Group

Proceeds Purpose
Proceeds from this capital infusion enable the advancement of 3-V's oncology clinical trials being performed as monotherapy and in combination with cytotoxic agents through phase IB expansion cohorts. The results obtained will bring 3-V to a value inflection point with a randomized phase II study being the potential next development milestone. In addition, the Company expects to conclude preclinical and IND-enabling work for the second program derived from their drug-discovery platform for regulatory (IND or CT) filing in 2015.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3715 Haven Ave. 220
Menlo Park, CA 94025
USA
Phone
(650) 561-8600
Website
www.3vbio.com
Email Address
[email protected]
Overview
3-V Biosciences is a biopharmaceutical company developing therapeutics for the treatment of infectious diseases.
Profile
3-V Biosciences LinkedIn Company Profile
Social Media
3-V Biosciences Company Twitter Account
Company News
3-V Biosciences News
Facebook
3-V Biosciences on Facebook
YouTube
3-V Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
George Kemble
  George Kemble LinkedIn Profile  George Kemble Twitter Account  George Kemble News  George Kemble on Facebook
Chief Medical Officer
William McCulloch
  William McCulloch LinkedIn Profile  William McCulloch Twitter Account  William McCulloch News  William McCulloch on Facebook
Vice President
Douglas Buckley
  Douglas Buckley LinkedIn Profile  Douglas Buckley Twitter Account  Douglas Buckley News  Douglas Buckley on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/31/2014: MiTu venture capital transaction
Next: 12/31/2014: Conjur venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to report on all VC transactions involving tech companies. VC transactions reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.